Drug Profile
AVE 8923
Alternative Names: AVE 8923A; AVE8923Latest Information Update: 18 Mar 2009
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Antiasthmatics
- Mechanism of Action Beta tryptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 13 Feb 2007 Phase-I clinical trials in Asthma (unspecified route)
- 16 Sep 2005 This programme is still in active development